News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Jul 7, 2020

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
Jun 30, 2020

InMed Announces Completion of Share Consolidation
Jun 24, 2020

InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System
Jun 19, 2020

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
May 27, 2020

InMed Releases CBN Preclinical Results in Glaucoma
May 19, 2020

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
May 14, 2020

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
May 12, 2020

InMed Files PCT Patent Application for Neuroprotection in Glaucoma
May 8, 2020

Notice of Telephone Scam Impersonating InMed
May 8, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020
May 7, 2020

InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference
May 5, 2020

InMed and Almac Group Developing Improved Cannabinoid Production Methods
Apr 30, 2020

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
Apr 1, 2020

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Mar 24, 2020

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
Mar 20, 2020

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
Mar 10, 2020

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Feb 14, 2020

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
Feb 7, 2020

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020
Jan 21, 2020

InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
Jan 20, 2020

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials
Jan 16, 2020

InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress
Jan 10, 2020

InMed Announces Election of Directors
Jan 8, 2020

InMed Pharmaceuticals to Present at the Biotech Showcase Conference
Dec 9, 2019

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa
Nov 11, 2019

InMed Pharmaceuticals to Present at the Cowen Conference
Nov 8, 2019

InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
Nov 5, 2019

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
Nov 4, 2019

InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019
Oct 18, 2019

InMed Pharmaceuticals to Present at the BIO Investor Forum
Sep 23, 2019

InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference
Sep 19, 2019

InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results and Provides R&D and Business Update
Sep 12, 2019

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2019 Financial Results and Business Update on September 19, 2019
Sep 3, 2019

InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aug 29, 2019

InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
Aug 2, 2019

InMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announces other Leadership Changes
Jul 2, 2019

InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
May 15, 2019

InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
May 8, 2019

InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019
Mar 18, 2019

InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
Mar 13, 2019

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
Mar 12, 2019

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019
Mar 6, 2019

InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board
Feb 12, 2019

InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
Feb 5, 2019

InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019
Jan 11, 2019

InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer
Jan 3, 2019

InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019
Dec 4, 2018

InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program
Nov 12, 2018

InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
Nov 5, 2018

InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018
Nov 5, 2018

InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls
Oct 10, 2018

InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018
Oct 3, 2018

InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up
Sep 25, 2018

InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
Sep 13, 2018

InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
Sep 11, 2018

InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
Sep 10, 2018

InMed Files Patent Application for its Cannabinoid Biosynthesis Program
Sep 7, 2018

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
Aug 31, 2018

InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Aug 1, 2018

InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
Jun 21, 2018

InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option
May 29, 2018

InMed to Present at the 8th Annual LD Micro Invitational Conference
May 14, 2018

InMed Files Patent Application for INM-085 Glaucoma Program
May 11, 2018

InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
May 1, 2018

InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board
Apr 17, 2018

InMed Rings the Opening Bell at the Toronto Stock Exchange
Apr 11, 2018

InMed Announces Appointment of Joshua Blacher as Chief Business Officer
Mar 23, 2018

InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Mar 13, 2018

InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development
Mar 12, 2018

InMed to Present at 30th Annual ROTH Capital Conference
Mar 6, 2018

InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Mar 2, 2018

InMed Receives Conditional Approval to List on the Toronto Stock Exchange
Jan 23, 2018

InMed To Present At Canaccord Genuity Conference
Jan 4, 2018

InMed Closes Over-Subscribed C$9.4 Million Financing
Dec 20, 2017

InMed Clarifies 3rd Party News Coverage
Dec 18, 2017

InMed Announces Non-Brokered Private Placement
Nov 16, 2017

InMed to Present at Cannabis-Based Science & Medicine Conference
Oct 24, 2017

InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid
Oct 17, 2017

InMed Updates Pain Program
Oct 10, 2017

InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board
Oct 3, 2017

InMed Pharmaceuticals Files Provisional Patent for Pain Program
Sep 25, 2017

InMed Continues to Make Significant Strides on Biosynthesis Program Development
Sep 21, 2017

InMed Pharmaceuticals Added to CSE25 Index
Sep 19, 2017

InMed Retains Consultant Ben Paterson for Biosynthesis Development
Sep 12, 2017

InMed Files Provisional Patent for Biosynthesis of Cannabinoids
Aug 18, 2017

InMed Announces Appointment of Creative Capital Media
Jul 27, 2017

InMed Announces Publication in European Journal of Pain
Jul 10, 2017

InMed Signs R&D Agreement with ATERA
Jun 13, 2017

InMed Announces Agreement to Advance a Topical Formulation of INM-750
May 31, 2017

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option
May 23, 2017

InMed Announces Pricing of $5,004,000 Underwritten Financing
May 10, 2017

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery
Apr 21, 2017

InMed Pharmaceuticals Announces Marketed Offering of Common Shares
Mar 24, 2017

InMed Pharmaceuticals Shareholders Approve New Stock Option Plan and Articles
Mar 8, 2017

InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference
Mar 2, 2017

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
Feb 27, 2017

InMed Receives over $1,350,000 From Warrant Exercise
Feb 9, 2017

InMed Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference
Jan 18, 2017

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000
Jan 13, 2017

InMed Pharmaceuticals Appoints Martin Bott to Board of Directors

Show per page

Investor

News Releases

Investor Alerts

Information Request

Stay up to Date

Investor

Investor Alerts

Information Request

Stay up to Date​

Stay up to Date